Ostankovitch M, Le Gal F A, Connan F, Chassin D, Choppin J, Guillet J G
Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM U445, Institut Cochin de Génétique Moléculaire, Université René Descartes, Paris, France.
Int J Cancer. 1997 Sep 17;72(6):987-94. doi: 10.1002/(sici)1097-0215(19970917)72:6<987::aid-ijc12>3.0.co;2-2.
This study investigates the generation of primary melanoma cell-specific cytotoxic T lymphocytes (CTLs) in vitro. Induction of peptide-specific CTLs from unfractionated naive peripheral blood mononuclear cells from HLA-A2 healthy donors was assessed using 2 recently described 9-mer epitopes from the melanoma tumor antigen Melan-A/MART-1. The need for help from CD4+ T lymphocytes for the long-lasting induction of CTLs and the capacity of the peptide-induced CTL lines to recognize many melanoma cells were evaluated. CTL lines were obtained reproducibly when CD4+ T-lymphocyte help was provided during the primary stimulation either in an autologous way, in the case of tetanus toxoid antigen (TT) responder donors, or with allogeneic TT-activated T-helper cells, separated by an insert well, in the case of tetanus toxoid non-responder donors. We also investigated helper T-cell-derived factors that are produced by TT-activated lymphocytes. Our results strongly suggest that a complex network of cytokines like interleukin-2 (IL-2), interferon-gamma, IL-6 and IL-1 exerts stimulatory effects for the initiation process of CTLs. In contrast, cytokine-like IL-4 might inhibit generation of cytolytic activity if provided by TT-activated T cells at early stages of induction. Our approach can be used to generate CTLs of a desired specificity for clinical use in adoptive immunotherapy protocols.
本研究在体外研究原发性黑色素瘤细胞特异性细胞毒性T淋巴细胞(CTL)的产生。使用来自黑色素瘤肿瘤抗原Melan-A/MART-1的2个最近描述的9聚体表位,评估从HLA-A2健康供体的未分级天然外周血单个核细胞诱导肽特异性CTL。评估了CD4+T淋巴细胞对CTL长期诱导的辅助需求以及肽诱导的CTL系识别多种黑色素瘤细胞的能力。当在初次刺激期间以自体方式(对于破伤风类毒素抗原(TT)应答者供体)或与通过插入孔分隔的同种异体TT激活的T辅助细胞(对于破伤风类毒素无应答者供体)提供CD4+T淋巴细胞辅助时,可重复获得CTL系。我们还研究了TT激活的淋巴细胞产生的辅助性T细胞衍生因子。我们的结果强烈表明,白细胞介素-2(IL-2)、干扰素-γ、IL-6和IL-1等细胞因子的复杂网络对CTL的起始过程发挥刺激作用。相比之下,如果在诱导早期由TT激活的T细胞提供,细胞因子样IL-4可能会抑制溶细胞活性的产生。我们的方法可用于产生具有所需特异性的CTL,用于过继免疫治疗方案的临床应用。